Mounjaro online prescription for weight loss

Mounjaro’s active ingredient, tirzepatide, is a glucagon-like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) dual agonist. Mounjaro was the first GLP-1/GIP approved by the FDA, followed only by Zepbound so far.

GLP-1 and GIP are natural hormones that hamper glucagon secretion, promote insulin secretion, and slow how fast food leaves the stomach. GLP-1/GIP dual agonists mimic these hormones and bind to GLP-1 and GIP receptors, which makes you want to eat less among other things.

Bottom line: when you use Mounjaro while eating a reduced-calorie diet and being more physically active, you improve blood sugar control, feel more full, and have less appetite, so you eat less and lose weight.

In clinical trials, people with type 2 diabetes lost up to 13.9% of their body weight in 104 weeks while taking 5, 10, or 15 milligrams of tirzepatide. In other studies, people without type 2 diabetes and with obesity or overweight lost up to 20.9% of their body weight in 72 weeks on 15 milligrams of tirzepatide.

Learn more about Mounjaro and how Mounjaro works for weight loss.

Like other injections for weight loss and type 2 diabetes, Mounjaro is taken once a week. It comes in 2.5-, 5.0-, 7.5-, 10.5-, 12.5-, and 15-milligram prefilled single-dose pens. You inject yourself under the skin, usually in your belly, upper thigh, or in the back of your arm. You can also have someone else inject you. 

When you start taking Mounjaro, you take 2.5 milligrams for the first 4 weeks. The smaller dose helps minimize side effects and lets your body adjust. After 4 weeks, you take the next higher dose for 4 weeks and so on until you reach your maximum dose, which may be 5 milligrams or more.

If you don’t tolerate Mounjaro well, your provider may have you increase your dose more slowly, for example, every 8 weeks. They may also have you step back to the next smaller dose as your maintenance dose. 

Learn more about Mounjaro and tirzepatide doses

Mounjaro is the same as Zepbound. Each is simply approved for different uses. They’re the only GLP-1/GIP dual agonist medications available. Ozempic and Wegovy are both GLP-1 receptor agonists and the same medication is used for different purposes and at different doses. 

In separate trials, people lost more weight on Mounjaro or Zepbound than other medications, including Ozempic, Wegovy, Saxenda (liraglutide), Qsymia (phentermine-topiramate), Contrave (bupropion-naltrexone), Adipex-P (phentermine), and Xenical (Orlistat). Mounjaro costs around $400 less a month than Ozempic or Wegovy, but about $10 more than Zepbound.

Whether you use Mounjaro or another medication, only you and your healthcare provider can decide which weight loss plan and medication, if applicable, is right for you. 

Saxenda, Contrave, Qsymia, Adipex-P, Xenical, and Wegovy are all FDA-approved for weight loss or weight management in people with obesity and overweight when combined with a reduced-calorie diet and increased physical activity. All have side effects that may include, but aren’t limited to, nausea, vomiting, constipation, diarrhea, and headaches. Phentermine is a controlled substance and can increase heart rate or blood pressure and cause dependency and misuse.

Read about Wegovy vs Mounjaro (aka Zepbound) and Saxenda vs Mounjaro.